Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.9600 (-2.18%) ($8.9600 - $8.9600) on Thu. Mar. 10, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.42% (three month average) | RSI | 32 | Latest Price | $8.9600(-2.18%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -6.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(77%) ARKG(72%) IBB(69%) ARKK(66%) IBUY(61%) | Factors Impacting TGTX price | TGTX will decline at least -3.71% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-26%) TBT(-12%) EDOC(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.71% (StdDev 7.42%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-5.47(-161.05%) | Resistance Level | $9.83 | 5 Day Moving Average | $8.81(1.7%) | 10 Day Moving Average | $9.35(-4.17%) | 20 Day Moving Average | $9.83(-8.85%) | To recent high | -56.2% | To recent low | 5.7% | Market Cap | $1.135b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |